It’s a rare thing
to care
Cutting-edge drugs for
calcium-related diseases
FIND MORE >
Ca++
is a crucial ion
in the regulation of numerous cellular processes in the human cells.
Its homeostasis is attentively regulated by several mechanisms, including the SOCE*.
*Store-Operated Calcium Entry
SOCE disregulation
leads to an unusual increase of intracellular Ca++ and is related to rare diseases such as
Tubular Aggregate Myopathies
1 : 100,000
globalprevalence
Duchenne Muscular Dystrophy
1 : 3,300
male globalincidence
and autoimmune and inflammatory diseases such as
Multiple Sclerosis
Rheumatoid Arthritis
Lupus
Atopic Dermatitis
Our cutting-edge
molecules
are innovative and highly selective chemical inhibitors of SOCE.
They are capable of reducing SOCE activity in a nanomolar range and therefore can be safely used as a treatment for related pathologies.
Good safety &
PK profile
IP
protection
Easy manufacturing
FIND MORE
Team
Founders
Beatrice Riva
CEO & CSO
Tracey Pirali
CTOBoard & Management
Marco Dieci
Board Member
Daniela Chicco
Board Member &Scientific Advisor
Nicola Pastori
Board Member & CFO
Demetra Pelos
Board Member &IP Portfolio Manager
Team
Luigi Azzarone
Head of R&D & Regulatory Affairs Responsible
Carlotta Muschitiello
Researcher
Emanuele Gallo
Lab Technician
Elena D'Apollo
Legal Affairs
Giovanni Gallian
Legal Affairs
Greta Vitali
Internship
Marco Cerina
InsternshipAdvisors
Maurizio Mariani
Scientific Advisor
Pier Luigi Canonico
Market Access &Pharmacology Advisor
Claudio Bruno
Clinical Advisor
Rita Di Martino
Medicinal Chemistry AdvisorValues
Sustainability
Addressing the current needs while safeguarding the capacity of future generations to fulfill their requirements is our imperative. Recognizing the environmental implications of our operations, we set forth explicit goals and viable solutions to meet the escalating demands responsibly.
Integrity
Exemplifying sincerity and upholding unwavering commitment to robust moral and ethical standards, we remain authentic to our core, refraining from any actions that may diminish or compromise our integrity.
News
ChemiCare Raises € 2.5 M Seed Round for the Development of a New Drug Candidate
ChemiCare, spin-off of the University of Piemonte Orientale (UPO), has closed a € 2.5 million investment round subscribed by CDP Venture Capital SGR S.p.A., Bio4Dreams S.p.A. and Bridge4Pharma S.r.l. with the aim of progressing its internal pipeline.
ChemiCare, UPO and AOU “Maggiore della Carità” together against multiple sclerosis
Funded by the Italian Multiple Sclerosis Foundation, the STOP-MS project is a multicenter study involving the Multiple Sclerosis Center of the “Maggiore della Carità” University Hospital and the Immunomics Laboratory at CAAD, part of the Department of Health Sciences at UPO.
ChemiCare drug candidate CIC-39 received the FDA orphan drug designation for Duchenne Muscular Dystrophy.
Food and Drug Administration
Beatrice Riva among the InspiringFifty Italy 2024 Winners.
Beatrice Riva, CEO of ChemiCare, was among the fifty women recognized as role models this year by InspiringFifty Italy 2024.
ChemiCare in Silicon Valley for CALL4INNOVIT.
ChemiCare was selected by INNOVIT – Italian Innovation and Culture Hub to take part at CALL4INNOVIT, the acceleration program dedicated to startup and scaleups in Life Sciences & Digital Health.
ChemiCare and Bridge4Pharma are joining forces into a partnership to push forward the development of pipeline initiatives.
Together with this alliance, Bridge4Pharma S.r.l., decided to invest in ChemiCare S.r.l.
ChemiCare has received the award “America Innovazione”
Corriere della Sera
ChemiCare drug candidate CIC-39 received the EMA orphan drug designation for Duchenne Muscular Dystrophy.
European Medicine AgencyChemiCare drug candidate CIC-39 received the EMA orphan drug designation for TAM and other calcium-related disease.
European Medicine Agency
Modulatori del SOCE, composizioni e loro usi
Università del Piemonte Orientale
ChemiCare – Beatrice Riva
Università del Piemonte Orientale
Intervista alla dottoressa Beatrice Riva di ChemICare
Biotecnologie News
ChemICare, nuova frontiera contro le malattie rare correlate al calcio
Bio4Dreams
Chemicare: seconda posizione e menzione speciale all’Italian Patent Competition
Innogest – Deloitte – Ministero per lo Sviluppo Economico
ChemiCare – Pharma for calcium regulation
Università del Piemonte Orientale
Le ricercatrici a caccia di molecole che combattono le malattie rare
La Stampa
Molecole contro le malattie rare. Premiata la ricerca novarese.
La Stampa
La start up Chemicare parteciperà al Premio Nazionale dell’Innovazione 2016
La Stampa
ChemiCare – Spin-off UPO
Università del Piemonte Orientale
Contact us
It's a rare thing
to care
ChemiCare S.r.l.
Registered Office:
📍 Corso Trieste 15/A, Novara, Italy
Operating Office:
📍 MIND - Viale Decumano 41, Palazzina 8, 20157, Milano, Italy
📍 Riva Tommaso Gulli 12, 34123, Trieste, Italy
VAT number: 02505930038
Mail: info@chemicare.it
